Research ExplorerPublicationsUse of phosphodiesterase type 5 inhibitors may adversely imp...

Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy

Standard

Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. / Michl, Uwe; Molfenter, Frederike; Graefen, Markus; Tennstedt, Pierre; Ahyai, Sascha; Beyer, Burkhard; Budäus, Lars; Haese, Alexander; Heinzer, Hans; Oh, Su Jung; Salomon, Georg; Schlomm, Thorsten; Steuber, Thomas; Thederan, Imke; Huland, Hartwig; Tilki, Derya.

In: J UROLOGY, Vol. 193, No. 2, 01.02.2015, p. 479-83.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Michl, U, Molfenter, F, Graefen, M, Tennstedt, P, Ahyai, S, Beyer, B, Budäus, L, Haese, A, Heinzer, H, Oh, SJ, Salomon, G, Schlomm, T, Steuber, T, Thederan, I, Huland, H & Tilki, D 2015, 'Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy', J UROLOGY, vol. 193, no. 2, pp. 479-83. https://doi.org/10.1016/j.juro.2014.08.111

APA

Michl, U., Molfenter, F., Graefen, M., Tennstedt, P., Ahyai, S., Beyer, B., Budäus, L., Haese, A., Heinzer, H., Oh, S. J., Salomon, G., Schlomm, T., Steuber, T., Thederan, I., Huland, H., & Tilki, D. (2015). Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J UROLOGY, 193(2), 479-83. https://doi.org/10.1016/j.juro.2014.08.111

Vancouver

Michl U, Molfenter F, Graefen M, Tennstedt P, Ahyai S, Beyer B et al. Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J UROLOGY. 2015 Feb 1;193(2):479-83. https://doi.org/10.1016/j.juro.2014.08.111

Bibtex

@article{c8da24a2a38b4ee5868e41b242fdbd73,
title = "Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy",
abstract = "PURPOSE: Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer.MATERIALS AND METHODS: The study was comprised of 4,752 consecutive patients with localized prostate cancer treated with bilateral nerve sparing radical prostatectomy between January 2000 and December 2010. Of these patients 1,110 (23.4%) received phosphodiesterase type 5 inhibitors postoperatively while 3,642 (76.6%) did not. The risk of biochemical recurrence was compared between the phosphodiesterase type 5 inhibitor group and the nonphosphodiesterase type 5 inhibitor group. Cox multivariate proportional hazard models and confidence intervals were used to estimate the hazard ratio of biochemical recurrence associated with phosphodiesterase type 5 inhibitor use. Propensity score matched analysis was performed.RESULTS: Median followup was 60.3 months (IQR 36.7-84.5). Five-year biochemical recurrence-free survival estimates in the phosphodiesterase type 5 inhibitor vs nonphosphodiesterase type 5 inhibitor groups were 84.7% (95% CI 82.1-87.0) and 89.2% (95% CI 88.1-90.3), respectively (p=0.0006). Multivariate regression analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR 1.38, 95% CI 1.11-1.70, p=0.0035) and this was also true after propensity score matching.CONCLUSIONS: Contrary to experimental data, the use of phosphodiesterase type 5 inhibitors after radical prostatectomy may adversely impact biochemical recurrence. Further studies are needed to validate our results.",
author = "Uwe Michl and Frederike Molfenter and Markus Graefen and Pierre Tennstedt and Sascha Ahyai and Burkhard Beyer and Lars Bud{\"a}us and Alexander Haese and Hans Heinzer and Oh, {Su Jung} and Georg Salomon and Thorsten Schlomm and Thomas Steuber and Imke Thederan and Hartwig Huland and Derya Tilki",
note = "Copyright {\textcopyright} 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2015",
month = feb,
day = "1",
doi = "10.1016/j.juro.2014.08.111",
language = "English",
volume = "193",
pages = "479--83",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy

AU - Michl, Uwe

AU - Molfenter, Frederike

AU - Graefen, Markus

AU - Tennstedt, Pierre

AU - Ahyai, Sascha

AU - Beyer, Burkhard

AU - Budäus, Lars

AU - Haese, Alexander

AU - Heinzer, Hans

AU - Oh, Su Jung

AU - Salomon, Georg

AU - Schlomm, Thorsten

AU - Steuber, Thomas

AU - Thederan, Imke

AU - Huland, Hartwig

AU - Tilki, Derya

N1 - Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - PURPOSE: Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer.MATERIALS AND METHODS: The study was comprised of 4,752 consecutive patients with localized prostate cancer treated with bilateral nerve sparing radical prostatectomy between January 2000 and December 2010. Of these patients 1,110 (23.4%) received phosphodiesterase type 5 inhibitors postoperatively while 3,642 (76.6%) did not. The risk of biochemical recurrence was compared between the phosphodiesterase type 5 inhibitor group and the nonphosphodiesterase type 5 inhibitor group. Cox multivariate proportional hazard models and confidence intervals were used to estimate the hazard ratio of biochemical recurrence associated with phosphodiesterase type 5 inhibitor use. Propensity score matched analysis was performed.RESULTS: Median followup was 60.3 months (IQR 36.7-84.5). Five-year biochemical recurrence-free survival estimates in the phosphodiesterase type 5 inhibitor vs nonphosphodiesterase type 5 inhibitor groups were 84.7% (95% CI 82.1-87.0) and 89.2% (95% CI 88.1-90.3), respectively (p=0.0006). Multivariate regression analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR 1.38, 95% CI 1.11-1.70, p=0.0035) and this was also true after propensity score matching.CONCLUSIONS: Contrary to experimental data, the use of phosphodiesterase type 5 inhibitors after radical prostatectomy may adversely impact biochemical recurrence. Further studies are needed to validate our results.

AB - PURPOSE: Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer.MATERIALS AND METHODS: The study was comprised of 4,752 consecutive patients with localized prostate cancer treated with bilateral nerve sparing radical prostatectomy between January 2000 and December 2010. Of these patients 1,110 (23.4%) received phosphodiesterase type 5 inhibitors postoperatively while 3,642 (76.6%) did not. The risk of biochemical recurrence was compared between the phosphodiesterase type 5 inhibitor group and the nonphosphodiesterase type 5 inhibitor group. Cox multivariate proportional hazard models and confidence intervals were used to estimate the hazard ratio of biochemical recurrence associated with phosphodiesterase type 5 inhibitor use. Propensity score matched analysis was performed.RESULTS: Median followup was 60.3 months (IQR 36.7-84.5). Five-year biochemical recurrence-free survival estimates in the phosphodiesterase type 5 inhibitor vs nonphosphodiesterase type 5 inhibitor groups were 84.7% (95% CI 82.1-87.0) and 89.2% (95% CI 88.1-90.3), respectively (p=0.0006). Multivariate regression analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR 1.38, 95% CI 1.11-1.70, p=0.0035) and this was also true after propensity score matching.CONCLUSIONS: Contrary to experimental data, the use of phosphodiesterase type 5 inhibitors after radical prostatectomy may adversely impact biochemical recurrence. Further studies are needed to validate our results.

U2 - 10.1016/j.juro.2014.08.111

DO - 10.1016/j.juro.2014.08.111

M3 - SCORING: Journal article

C2 - 25196656

VL - 193

SP - 479

EP - 483

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 2

ER -